FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes

Oncotarget
Sebastien RinaldettiPhilipp Erben

Abstract

Forkhead box M1 (FOXM1) is a late cell cycle gene that plays a crucial role in carcinogenesis and chemotherapeutic drug resistance. In this study, the impact of FOXM1 expression on patient outcome was investigated for the first time in formalin fixed and paraffin embedded (FFPE) samples of chemotherapy naïve muscle-invasive bladder cancer (MIBC) patients. Expression analyses were performed on the Mannheim cohort (n=84) and validated on the independent Chungbuk cohort (n=61). In a Cox' proportional hazards model, a distinct FOXM1 expression cut-off dividing both cohorts in a 'high-risk' and 'low-risk' group has been determined. Multivariate analyses showed that FOXM1 is an independent risk factor for outcome prediction superior to the TNM system. The FOXM1 'high-risk' group had a 4- to 7-fold increased risk of death (p<0.03) and presented further an overexpression of MKI67. Recent studies showed that MIBCs can be subclassified in breast cancer-like subtypes: basal, luminal and p53-like. Here we demonstrated that FOXM1 was differentially expressed between MIBC subtypes concordant to its subtype specific expression in breast cancer. Since the proto-oncogene FOXM1 is known to play an important role in cisplatin resistance and to be...Continue Reading

References

Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P SteinD G Skinner
Jan 18, 2005·Nature Cell Biology·Jamila LaoukiliRené H Medema
Jul 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans von der MaaseMichael Arning
Jan 10, 2006·Urology·Ziya KirkaliJeff Weider
Feb 19, 2008·Nature Biotechnology·Gary K GeissKrassen Dimitrov
Jan 15, 2009·Journal of the National Cancer Institute·Vitaly MargulisShahrokh F Shariat
May 15, 2009·PloS One·Uppoor G BhatAndrei L Gartel
Aug 13, 2009·PloS One·Uppoor G BhatAndrei L Gartel
Sep 15, 2009·Oncogene·A M Barsotti, C Prives
Oct 7, 2009·Cell Cycle·Bulbul PanditAndrei L Gartel
Jan 14, 2010·Molecular Cancer Research : MCR·Jimmy M-M KwokEric W-F Lam
Jun 10, 2010·Cancer Research·Janai R CarrPradip Raychaudhuri
Jan 5, 2011·EMBO Molecular Medicine·Hyun Jung ParkPradip Raychaudhuri
Jan 29, 2011·Cell Cycle·Tanya V KalinVladimir V Kalinichenko
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Feb 22, 2011·TheScientificWorldJournal·Ramy F Youssef, Yair Lotan
Mar 19, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jay B ShahColin P N Dinney
Apr 27, 2011·Molecular Cancer Therapeutics·Julie MillourEric W F Lam
May 4, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gottfrid SjödahlMattias Höglund
Oct 30, 2012·Biochemical Pharmacology·Marianna Halasi, Andrei L Gartel
Jan 18, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Dongye LiuChui-ze Kong
Feb 28, 2013·Molecular Cancer Therapeutics·Marianna Halasi, Andrei L Gartel
Jul 13, 2013·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·Trine TrammJan Alsner
Jan 30, 2014·European Urology·Robert S SvatekYair Lotan
Feb 13, 2014·Proceedings of the National Academy of Sciences of the United States of America·Jeffrey S DamrauerWilliam Y Kim
Jun 25, 2014·Nature Reviews. Urology·Woonyoung ChoiDavid J McConkey
Feb 3, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Xin-Sen XuChang Liu
May 27, 2015·BMC Medical Genomics·Pontus ErikssonMattias Höglund

❮ Previous
Next ❯

Citations

Jun 7, 2019·Der Urologe. Ausg. A·M C HupeR Seiler
Nov 30, 2018·Virchows Archiv : an International Journal of Pathology·Philipp ErbenUNKNOWN BRIDGE Consortium e.V.
Jul 1, 2018·Journal of Cancer Research and Clinical Oncology·Sebastien RinaldettiPhilipp Erben
Oct 30, 2018·Frontiers in Oncology·Matteo GiuliettiFrancesco Piva
Jan 26, 2021·Computational and Structural Biotechnology Journal·Joanna Hui Juan TanAxel M Hillmer

❮ Previous
Next ❯

Software Mentioned

JMP
Nanostring
Illumina BeadStudio
nSolver
SPSS

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.